Company news
Lobe Sciences Ltd (CSE:LOBE) news
Lobe Sciences Ltd news releases on 6ix. Latest, Sep 14, 2026: Lobe Sciences to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto
Press releases & updates
Lobe Sciences to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto
September 14, 2026
Lobe Sciences Ltd. Announces Closing of Upsize to Non-Brokered Private Placement
August 31, 2026
Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement
August 28, 2026
Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement
August 20, 2026
Lobe Sciences Reports Third Quarter 2026 Financial Results
August 18, 2026
Lobe Sciences Announces Results of Annual General and Special Meeting of Shareholders
August 5, 2026
Lobe Sciences Directors and Management Increase Equity Ownership Through Settlement of Accrued Fees by the Issuance of Common Shares
June 9, 2026
Lobe Sciences Announces Proposed Shares for Debt Transaction
June 1, 2026
Lobe Sciences Reports Second Quarter 2026 Results and Highlights Continued Operational Progress
May 6, 2026
Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement and Provides Corporate Update
April 20, 2026
Lobe Sciences Ltd. Announces Non-Brokered Private Placement
April 10, 2026
Lobe Sciences Ltd. Reports Improved Financial Position and Strategic Update
March 25, 2026
Lobe Sciences Announces Appointment of Mr. Mirza Rahimani, CPA, CA as Chief Financial Officer
March 8, 2026
Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences
March 5, 2026
Lobe Sciences Reports First Quarter 2026 Results and Highlights
February 3, 2026
Lobe Sciences Advances Governance and Capital Markets Expertise with Appointment of Mr. Nick Karakochuk to the Board of Directors
January 13, 2026
Lobe Sciences Reports FY2025 with a Stronger Balance Sheet and Sharpened Strategy
January 8, 2026
Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition
January 6, 2026
Lobe Sciences Completes Debt Settlement to Improve Balance Sheet
October 23, 2025
Lobe Sciences Improves Balance Sheet
October 9, 2025
Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto
September 14, 2025
Lobe Sciences Ltd. and Cynaptec Pharmaceuticals, Inc. to Present a New Therapeutic Approach for the Treatment of Chronic Cluster Headaches at Clusterbusters 2025
September 9, 2025
Lobe Sciences Announces the Appointment of Marco Mastrodonato to its Board of Directors
September 8, 2025
Lobe Sciences Announces the Closing of the Previously Announced Private Placement
August 14, 2025
Lobe Sciences Announces $341,425 CAD Private Placement for General Corporate Purposes
July 29, 2025
Lobe Sciences Ltd. Engages ArcStone Securities for Strategic Capital Markets Advisory
July 29, 2025
Lobe Sciences Ltd. Announces Debt Settlement
July 16, 2025
Lobe Sciences Announces Validation of European Unitary Patent for DHA-Based Composition for Sickle Cell Disease
July 8, 2025
Lobe Sciences Moves Forward with Development of Conjugated Psilocin(TM) Following April 14 Agreement to Spin Out Compound to Cynaptec Pharmaceuticals
June 17, 2025
Lobe Sciences Appoints Mr. Yong Yao as Chief Financial Officer to Support Strategic Growth
June 3, 2025
Lobe Sciences Ltd. Announces Private Placement to Support Drug Development of Novel Conjugated Psilocin
April 15, 2025
Lobe Sciences Ltd. Announces Private Placement to Support Drug Development of Novel Conjugated Psilocin(TM)
April 14, 2025
Lobe Sciences Provides Corporate Update
April 4, 2025
Lobe Sciences and Alera Pharma Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™
November 18, 2024
Lobe Sciences, Ltd. Announces the Appointment of Enclave Capital and Peak Asset Management to Fund Clinical Trials of Conjugated Psilocin™
October 16, 2024
Lobe Sciences and Alera Pharma Announce Issuance of U.S. Patent for Conjugated Psilocin
October 3, 2024
Lobe Sciences Announces Creation of Wholly Owned Subsidiary, Alera Pharma, Inc.
August 15, 2024
Lobe Sciences Announces Appointment of a New Board of Directors and Executive Management Team
August 12, 2024
Lobe Sciences Announces Update
June 4, 2024
Wesley Ramjeet to Join Lobe Sciences’ Board of Directors, Bringing Decades of Strategic Financial Expertise
June 3, 2024
Lobe Sciences Announces Frederick D. Sancilio Ph.D. to Join Board of Directors
May 31, 2024
Former Merck Director and Vanderbilt Vice-Chancellor, Dr. Harry Jacobson, to Join Lobe Sciences Board of Directors
May 30, 2024
Lobe Sciences Ltd. and Clearway Global Announce Change of Control and Focus on Creating Value for Shareholders
May 21, 2024
Lobe Sciences Provides Company Review of 2023
January 8, 2024
Lobe Sciences Provides Update on L-130 Clinical Program
December 7, 2023
Lobe Sciences Announces Additional Details Regarding the Acquisition of Altemia(TM) & Company
June 29, 2023
Lobe Sciences, Ltd. Provides Update on Vitamind
April 21, 2023
Lobe Sciences, Ltd. Announces the Acquisition of Altemia(TM) & Company
April 18, 2023
Lobe Sciences to Present at Sequire Cannabis & Psychedelics Conference April 5, 2023
April 4, 2023
Lobe Sciences Ltd. Announces That The Drug Enforcement Administration Has Issued The Initial 2023 Quota Allowing Export Of L-130
March 22, 2023